Published online before print May 17, 2004, doi: 10.1161/01.CIR.0000130926.51766.CC
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2749-2754.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
From the Cardiology (D.C., A.C., N.C., M.B., G.L., M.C., C.F., C.M.C.) and Laboratory Medicine Units (M.T.S.), Hemato-Oncology Division (F.P., G.M.), Istituto Europeo di Oncologia, University of Milan, Milan, Italy.
Correspondence to Daniela Cardinale, MD, Cardiology Unit, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy. E-mail daniela.cardinale{at}ieo.it
Received September 18, 2003; revision received January 9, 2004; accepted February 24, 2004.
Background— In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left ventricular dysfunction. The time course of the subclinical myocardial damage and its impact on the clinical outcome have never been investigated previously.
Methods and Results— In 703 cancer patients, we measured TnI soon after chemotherapy (early TnI) and 1 month later (late TnI). Troponin was considered positive for values 
0.08 ng/mL. Clinical and left ventricular ejection fraction evaluation (echocardiography) were performed before chemotherapy, 1, 3, 6, and 12 months after the end of the treatment, and again every 6 months afterward. Three different TnI patterns were identified, and patients were grouped accordingly. In 495 patients, both early and late TnI values were <0.08 ng/mL (TnI–/– group); in 145, there was only an early increase (TnI+/– group); and in 63 patients, both values increased (TnI+/+ group). In the TnI–/– group, no significant reduction in ejection fraction was observed during the follow-up, and there was a very low incidence of cardiac events (1%). In contrast, a greater incidence of cardiac events occurred in TnI-positive patients, particularly in the TnI+/+ group (84% versus 37% in the TnI+/– group; P<0.001).
Conclusions— TnI release pattern after high-dose chemotherapy identifies patients at different risks of cardiac events in the 3 years thereafter. This stratification allows us to differentiate the monitoring program and to plan, in selected patients, preventive strategies aimed at improving clinical outcome.
Key Words: troponin • chemotherapy • ventricles • cardiac toxicity
This article has been cited by other articles:
 |
|
 |
|
  J. R. Carver, S. J. Schuster, and J. H. Glick Doxorubicin Cardiotoxicity in the Elderly: Old Drugs and New Opportunities J. Clin. Oncol., July 1, 2008; 26(19): 3122 - 3124. [Full Text] [PDF]
|
|
|
|
 |
|
 T Chung, W-C Lim, R Sy, I Cunningham, J Trotman, and L Kritharides Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function Heart, July 1, 2008; 94(7): 911 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Ewer and D. J. Lenihan Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground? J. Clin. Oncol., March 10, 2008; 26(8): 1201 - 1203. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics, February 1, 2008; 121(2): e387 - e396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey Early Breast Cancer Therapy and Cardiovascular Injury J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1435 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. de Bree, S. van Ruth, C. E. Schotborgh, P. Baas, and F. A. N. Zoetmulder Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin Ann. Surg. Oncol., October 1, 2007; 14(10): 3019 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Jones, M. Haykowsky, E. N. Pituskin, N. G. Jendzjowsky, C. R. Tomczak, R. G. Haennel, and J. R. Mackey Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer Oncologist, October 1, 2007; 12(10): 1156 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, M. Deidda, R. Serpe, E. Massa, and G. Mantovani Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, September 1, 2007; 12(9): 1124 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, C. M. Cipolla, F. Veglia, and C. Fiorentini Response to Letter Regarding Article, "Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition" Circulation, June 19, 2007; 115(24): e638 - e638. [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy: Can It Be Done? Circulation, December 5, 2006; 114(23): 2432 - 2433. [Full Text] [PDF]
|
|
|
|
|
|
D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cardinale, G. Lamantia, and C. M. Cipolla Troponin I and Cardiovascular Risk Stratification in Patients With Testicular Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3508 - 3508. [Full Text] [PDF]
|
|
|
|
|
|
E. C. de Haas, J. Nuver, M. P. van den Berg, A. J. Smit, D. Th. Sleijfer, and J. A. Gietema In Reply J. Clin. Oncol., July 20, 2006; 24(21): 3508 - 3509. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, M. Civelli, and C. M. Cipolla Troponins in prediction of cardiotoxic effects Ann. Onc., January 1, 2006; 17(1): 173 - 173. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Babuin and A. S. Jaffe Troponin: the biomarker of choice for the detection of cardiac injury Can. Med. Assoc. J., November 8, 2005; 173(10): 1191 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Ewer, M. T. Vooletich, J.-B. Durand, M. L. Woods, J. R. Davis, V. Valero, and D. J. Lenihan Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment J. Clin. Oncol., November 1, 2005; 23(31): 7820 - 7826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sandri, M. Salvatici, D. Cardinale, L. Zorzino, R. Passerini, P. Lentati, M. Leon, M. Civelli, G. Martinelli, and C. M. Cipolla N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction? Clin. Chem., August 1, 2005; 51(8): 1405 - 1410. [Abstract] [Full Text] [PDF]
|
|